| Ticker: | IPHA |
| Current Price: | $1.43 |
| % Daily Change: | -2.72% |
| Volume (1,000s): | 9.28 |
| Average Volume (1,000s): | 67.65 |
| Market Cap (M): | $134.28 |
| 1/2/2024 Price: | $5.72 |
| Change Since Inception: | -75.00% |
Innate Pharma S.A.
117, Avenue de Luminy
BP 30191
Marseille, 13009
France
Innate Pharma S.A. is a global, clinical-stage oncology-focused biotech company dedicated to improving treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer. Innate Pharma’s broad pipeline of antibodies includes several potentially first-in-class clinical and preclinical candidates in cancers with high unmet medical need. Innate has been a pioneer in the understanding of natural killer cell (NK cell) biology and has expanded its expertise in the tumor microenvironment and tumor-antigens, as well as antibody engineering. This innovative approach has resulted in a diversified proprietary portfolio and major alliances with leaders in the biopharmaceutical industry including Bristol-Myers Squibb Novo Nordisk A/S, Sanofi, and a multi-products collaboration with AstraZeneca. Based in Marseille, France, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.